An observational study in Diabetes Mellitus, Type 2, sponsored by AstraZeneca. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-20.
Sponsored by AstraZeneca · Observational
The purpose of this study is to compare the incidence of hospitalization with acute liver failure among patients with type 2 diabetes who are new users of Saxagliptin and those who are new users of other oral antidiabetic drugs.
Prospectively designed retrospective database study. This study will be conducted using administrative claims data and electronic medical records that are collected as part of routine clinical practice
445 studies on the registry are indexed under Liver Failure; 69 are open to participants now.
This study's enrollment of 113,505 is above the median of 129 across 146 observational studies indexed under Liver Failure.
Browse Liver Failure studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
This study will be carried out using databases containing administrative claims data (HealthCore Integrated Research DatabaseSM (HIRD) and Medicare in the U.S.) and electronic medical records (General Practice Research Database (GPRD) and The Health Improvement Network (THIN) in the UK). The US population includes patients from health plans in the northeast, southeastern, mid-Atlantic, central, mid-western, and western regions (HIRD) as well as US citizens 65 years of age and older (Medicare). The UK population includes patients seeking medical care from general practitioners (GPRD and THIN)
Exclusion Criteria:
Number of participants hospitalized with a diagnosis of acute liver failure
Time frame: 18-months
Number of participants hospitalized with a diagnosis of acute liver failure
Time frame: 36-months
Number of participants hospitalized with a diagnosis of acute liver failure
Time frame: 54-months
Deaths due to acute liver failure
Time frame: 18, 36 and 54 months
Hospitalizations with acute liver failure and/or death due to acute liver failure
Time frame: 18, 36 and 54 months
Hospitalizations with acute liver injury
Time frame: 18, 36 and 54 months
No study locations are listed for this record.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca